Navigation Links
Novel technique switches triple-negative breast cancer cells to hormone-receptor positive cells
Date:11/1/2011

Within many hormone-receptor positive breast cancers lives a subpopulation of receptor-negative cells knock down the hormone-receptor positive cells with anti-estrogen drugs and you may inadvertently promote tumor takeover by more dangerous, receptor-negative cells. A study recently published in the Proceedings of the National Academy of Sciences describes how to switch these receptor-negative cells back to a state that can be targeted by existing hormone therapies.

"We found that these estrogen-receptor negative cells express high levels of a Notch receptor protein," says James Haughian, PhD, investigator at the University of Colorado Cancer Center and instructor at the University of Colorado School of Medicine. "And when you blockade this Notch activity, you end up with a pure population of hormone-receptor positive cells."

Very basically, within a breast cancer, you frequently have different kinds of cells living together some that have estrogen receptors and so need to "grab" estrogen in order to survive, grow and replicate. And, Haughian finds, some with similar Notch receptors that need to "grab" Notch proteins in order to survive, grow and replicate. On these cells without estrogen receptors but with Notch receptors, blockade this Notch pathway and the cell again becomes dependent on estrogen and thus likely treatable with anti-estrogen therapies.

"It's rare to get something that works so fantastically well as this," Haughian says.

Whether this switch from hormone-insensitive to hormone-sensitive is due to basic evolution killing the triple-negative cells leaves more resources for the growth of hormone-receptor positive cells or whether inhibiting Notch signaling, in fact, causes triple-negative cells to grow hormone receptors is still under investigation.

Whatever the precise mechanism, drugs that inhibit this Notch activity are already in clinical trials for breast cancer. However, Kathryn Horwitz, PhD, investigator at the CU Cancer Center and Distinguished Professor of Endocrinology at the University of Colorado School of Medicine theorizes that, "monotherapy with a Notch inhibitor might not be enough on its own, but may convert the cancer into a hormone-therapy treatable state."

This finding that Notch inhibition converts a triple-negative cancer subpopulation to a hormone-receptor positive population implies the potential usefulness of combination therapy perhaps a Notch inhibitor to make all the cancer's cells hormone-sensitive, followed by an anti-estrogen to treat them.

"Theorizing that and proving it is another matter," Horwitz says. "But if a clinician came knocking on our door, we'd say hey, let's try it."


'/>"/>
Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver
Source:Eurekalert

Related biology news :

1. The Michael J. Fox Foundation awards nearly $200,000 to develop novel drugs for Parkinsons disease
2. Novel technique uses RNA interference to block inflammation
3. La Jolla Institute discovers novel mechanism for preventing infection via bodys mucosal borders
4. Novel drug combination offers therapeutic promise for hard-to-treat cancers
5. Novel approach scores first success against elusive cancer gene
6. Novel method for increasing antibiotic yields
7. Tropical coral could be used to create novel sunscreens for human use, say scientists
8. A novel mechanism that regulates pro-inflammatory cells is identified
9. Novel analysis by Allen Institute sheds new light on the mechanisms of brain development
10. Novel gene increases yeasts appetite for plant sugars
11. Life scientists use novel technique to produce genetic map for African Americans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... March 30, 2017  On April 6-7, 2017, Sequencing.com ... Genome hackathon at Microsoft,s headquarters in ... will focus on developing health and wellness apps that ... Hack the Genome is the first hackathon for ... world,s largest companies in the genomics, tech and health ...
(Date:3/29/2017)... -- higi, the health IT company that operates the largest ... , today announced a Series B investment from BlueCross ... new investment and acquisition accelerates higi,s strategy to create ... health activities through the collection and workflow integration of ... and secures data today on behalf of over 36 ...
(Date:3/24/2017)... The Controller General of Immigration from Maldives Mr. Mohamed Anwar ... prestigious international IAIR Award for the most innovative high security ePassport and ... ... Maldives Immigration Controller General, Mr. Mohamed ... the right) have received the IAIR award for the "Most innovative high ...
Breaking Biology News(10 mins):
(Date:9/21/2017)... Paramus, New Jersey (PRWEB) , ... September 21, ... ... for highly-regulated pharmaceutical and clinical research sector professionals, has announced the addition of ... CFR Part 11 training - Compliance with Regulation 21 CFR Part 11 ...
(Date:9/20/2017)... ... 20, 2017 , ... Cybrexa Therapeutics , a start-up ... role of chief scientific officer. In this role, Dr. Paralkar will lead the ... CEO, Per Hellsund. , “I was impressed with Cybrexa’s revolutionary technology and excellent ...
(Date:9/20/2017)... ... September 20, 2017 , ... From industry leaders, sports stars, ... standard medicine failed. Many of these people had lost all hope. Their ... Free Download (pdf) , “Neil takes readers on a riveting journey ...
(Date:9/19/2017)... Philadelphia, PA (PRWEB) , ... September 19, 2017 ... ... are joining Philadelphia’s largest group of funded early-stage tech companies. “Grit” author Angela ... anchor tenant. Also joining the ic@3401 community is Cooley, an international law firm ...
Breaking Biology Technology: